WASHINGTON — A blood test could predict whether apparently healthy older people have chances of developing symptoms of Alzheimer’s in the next five or ten yearsas reported by researchers this Wednesday.
This information could be reassuring or terrifying, but, For now, it is a potential tool to accelerate drug developmentas it helps identify and include high-risk people in studies on possible treatments or preventive strategies against Alzheimer’s.
Large-scale clinical trials are already underway to test whether certain medications could prevent or at least delay the disease; And if any of them work, doctors will need a simple way to determine who should try them.
1 / 25 | These foods can slow aging. Many “anti-aging” foods are packed with antioxidants, vitamins, minerals, and healthy fats.
The scientists behind the new study emphasize that it is too early for healthy people to undergo the so-called p-tau217 test, which It is currently used to help diagnose whether people who suffer from cognitive problems have Alzheimer’s or another disorder.
“Wait and get tested when you can still do something about it,” stressed Dr. Reisa Sperling, from the Mass General Brigham Neuroscience Institute and lead author of the study. “At this point, that wouldn’t change what I would tell someone to do it. I would still advise them to eat well, sleep well, get plenty of exercise and stay active.”
The new findings revealed that asymptomatic older people with very high levels of p-tau217 had a 38% risk of developing cognitive impairment within a period of five years. That risk increased to 78% at 10 years.
The study was published in the journal JAMA and presented at the Alzheimer’s Association International Conference in London.
The exact cause of Alzheimer’s is unclear, but its hallmark markers are amyloid plaques, which clog the brain, and tau tangles, which destroy neurons. The p-tau217 test measures a form of tau that correlates with the amount of plaque buildup a person has and provides an indication of tangles, Sperling explained.
The Mass General Brigham team analyzed data from 2,684 older people who were in good health when they joined several long-term Alzheimer’s studies, who had the p-tau217 blood test at enrollment and underwent annual cognitive screenings. Between the first registration, in 2004, and last year, some 478 had developed cognitive impairment.
Study participants with very low levels of p-tau217 also had a low risk of developing cognitive decline during that five to 10-year period.
Predicting Alzheimer’s poses a conundrum: many people have high levels of amyloid plaques and yet never develop dementia. One of the most widely accepted theories is that, at some point, amyloid buildup causes the formation of an abnormal type of tau protein that gives rise to neurofibrillary tangles, which in turn causes symptoms.
Sperling said the blood test data offers some new clues. Although the various intermediate levels of p-tau217 indicated a progressive risk, only the highest level seemed to correlate with other clues about that inflection point.
“It is a gradual process in which amyloid and tau protein accumulate in the brain, and this blood biomarker indicates which phase of that process you are in,” he explained.
Scientists not involved in the study praised it, but also pointed out some reasons for caution. One is that only a small portion of participants had been followed for a full decade, making the 10-year risk estimate less reliable than the five-year risk estimate.
In addition, the predictions could be affected by other factors: Older people may be at risk of dying from other causes or suffering from heart problems that can lead to vascular dementia instead of Alzheimer’s disease, Dr. Suzanne Schindler of Washington University in St. Louis and David Wolk of the University of Pennsylvania noted in a commentary published in JAMA.
Blood tests “are not yet accurate enough to guide an individualized prognosis,” Schindler — who is also studying the prognostic potential of p-tau217 — and Wolk wrote. However, they stated that this new work has “provided a crucial piece of the puzzle.”
“There are already people who come and tell us: “I want to do this blood test. “I have a family history of Alzheimer’s disease,” said Jessica Langbaum of the Banner Alzheimer’s Institute in Phoenix, something she strongly advises against—for now.
“These results are quite solid”Langbaum added, and a predictive blood test would be “really important,” but only if ongoing studies eventually find a drug that can help people before symptoms appear.
This story was translated from English to Spanish with an artificial intelligence tool and was reviewed by an editor before publication.
